Development asset linked to Bausch + Lomb in public FDA and regional records.
pharma · Plaque Psoriasis · Diabetic Macular Edema
Bausch + Lomb
Bausch & Lomb Incorporated
Bausch + Lomb drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Rochester, IN HQ
1853 Founded
38 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Rochester, IN
- Founded
- 1853
- Employees
- 38
- Programs
- 3
- Drugs
- 5
- Patents
- 25
Bausch + Lomb pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Bausch + Lomb drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Bausch + Lomb in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor